Literature DB >> 10973960

Identification of connective tissue growth factor as a target of WT1 transcriptional regulation.

P Stanhope-Baker1, B R Williams.   

Abstract

The Wilms tumor suppressor WT1 has transcription-activating and -suppressing capabilities. WT1-responsive promoters have been described; however, in large part, it remains unclear which potential downstream genes are physiologically relevant and mediate the function of WT1 in tumorigenesis and development. To identify genes regulated by WT1 in vivo, we used a dominant-negative version of WT1 to modulate WT1 activity in a Wilms tumor cell line. Screening oligonucleotide arrays with RNA from these cells uncovered a number of genes whose expression was altered by abrogation of WT1 function. Several of the genes encode members of the CCN family of growth regulators. The promoter of one of these genes, connective tissue growth factor (CTGF), is suppressed by WT1 both in its endogenous location and in reporter constructs. WT1 regulation of CTGF expression is not mediated by previously identified WT1 recognition elements and may therefore involve a novel mechanism. Our results indicate that CTGF is a bona fide target of WT1 transcriptional suppression and likely plays a role in Wilms tumorigenesis and associated disease syndromes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973960     DOI: 10.1074/jbc.M004901200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues.

Authors:  B Perbal
Journal:  Mol Pathol       Date:  2001-04

2.  Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells.

Authors:  J S Oh; J E Kucab; P R Bushel; K Martin; L Bennett; J Collins; R P DiAugustine; J C Barrett; C A Afshari; S E Dunn
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

3.  The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts.

Authors:  A Leask; S Sa; A Holmes; X Shiwen; C M Black; D J Abraham
Journal:  Mol Pathol       Date:  2001-06

4.  TGFbeta1 induces epithelial-mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary culture.

Authors:  Monica Forino; Rossella Torregrossa; Monica Ceol; Luisa Murer; Manuela Della Vella; Dorella Del Prete; Angela D'Angelo; Franca Anglani
Journal:  Int J Exp Pathol       Date:  2006-06       Impact factor: 1.925

Review 5.  Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis.

Authors:  Andrew Leask; Alan Holmes; David J Abraham
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

6.  CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.

Authors:  Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

7.  WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression.

Authors:  Debra J Morrison; Marianne K H Kim; Windy Berkofsky-Fessler; Jonathan D Licht
Journal:  Mol Cancer Res       Date:  2008-07       Impact factor: 5.852

8.  Expression of connective tissue growth factor (CCN2) in desmoplastic small round cell tumour.

Authors:  A W Rachfal; M H Luquette; D R Brigstock
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

9.  A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis.

Authors:  Nathalie Planque; Bernard Perbal
Journal:  Cancer Cell Int       Date:  2003-08-22       Impact factor: 5.722

10.  In silico regulatory analysis for exploring human disease progression.

Authors:  Dustin T Holloway; Mark Kon; Charles DeLisi
Journal:  Biol Direct       Date:  2008-06-18       Impact factor: 4.540

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.